These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15728776)

  • 1. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
    Bennett WM
    J Am Soc Nephrol; 2005 Apr; 16(4):838-9. PubMed ID: 15728776
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolvaptan in autosomal dominant polycystic kidney disease.
    Jouret F; Krzesinski JM
    N Engl J Med; 2013 Mar; 368(13):1258-9. PubMed ID: 23534572
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolvaptan in autosomal dominant polycystic kidney disease.
    Sexton DJ
    N Engl J Med; 2013 Mar; 368(13):1258. PubMed ID: 23534571
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolvaptan in autosomal dominant polycystic kidney disease.
    Kher A
    N Engl J Med; 2013 Mar; 368(13):1257-8. PubMed ID: 23534570
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolvaptan in autosomal dominant polycystic kidney disease.
    Spital A
    N Engl J Med; 2013 Mar; 368(13):1257. PubMed ID: 23534569
    [No Abstract]   [Full Text] [Related]  

  • 6. Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
    Devuyst O; Wang X; Serra A
    Nephrol Dial Transplant; 2011 Aug; 26(8):2423-5. PubMed ID: 21803730
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.
    Kawada T
    Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257
    [No Abstract]   [Full Text] [Related]  

  • 8. Tolvaptan in autosomal dominant polycystic kidney disease.
    Torres VE; Gansevoort RT; Czerwiec FS
    N Engl J Med; 2013 Mar; 368(13):1259. PubMed ID: 23534568
    [No Abstract]   [Full Text] [Related]  

  • 9. Aquaretic treatment in polycystic kidney disease.
    Wüthrich RP; Mei C
    N Engl J Med; 2012 Dec; 367(25):2440-2. PubMed ID: 23121376
    [No Abstract]   [Full Text] [Related]  

  • 10. In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease".
    Horie S; Muto S
    Clin Exp Nephrol; 2016 Feb; 20(1):149-50. PubMed ID: 26586005
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cystic kidneys can now be treated].
    Schumacher B
    MMW Fortschr Med; 2015 Sep; 157(15):26. PubMed ID: 26349712
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
    Lacquaniti A
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 25083527
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability.
    Meijer E; Gansevoort RT
    Kidney Int; 2020 Aug; 98(2):289-293. PubMed ID: 32709290
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?
    Reddy B; Chapman AB
    Am J Kidney Dis; 2015 Jun; 65(6):811-3. PubMed ID: 26003607
    [No Abstract]   [Full Text] [Related]  

  • 15. [New strategy for the treatment of autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2015; 57(1):254-61. PubMed ID: 25735085
    [No Abstract]   [Full Text] [Related]  

  • 16. Autosomal dominant polycystic kidney disease.
    Simms RJ
    BMJ; 2016 Feb; 352():i679. PubMed ID: 26868522
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with tolvaptan in patients with polycystic kidney disease.
    López Del Moral Cuesta C; Fernández Fresnedo G; Martín Penagos L
    Med Clin (Barc); 2020 Jul; 155(2):83-84. PubMed ID: 31130311
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease.
    Bergmann C; Frank V; Küpper F; Kamitz D; Hanten J; Berges P; Mager S; Moser M; Kirfel J; Büttner R; Senderek J; Zerres K
    Mol Diagn Ther; 2006; 10(3):163-74. PubMed ID: 16771602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.